(redirected from placentally)
Also found in: Dictionary, Thesaurus.


Relating to the placenta.
Farlex Partner Medical Dictionary © Farlex 2012

hydrops fetalis

Kernicterus, Rh incompatibility, Rh-induced hemolytic disease of newborn Obstetrics An accumulation of fluid in neonates, resulting in a 'puffy', plethoric or hydropic appearance that may be due to various etiologies Clinical Ascites, edema, ↓ protein or chronic intrauterine anemia, hepatosplenomegaly, cardiomegaly, extramedullary hematopoiesis, jaundice, pallor COD Heart failure. See Hemolytic disease of the newborn.
Hydrops Fetalis, causes
Immune Mother produces IgG antibodies against infant antigen(s), often an RBC antigen, most commonly, anti-RhD, which then passes into the fetal circulation, causing hemolysis
Non-immune Hydrops may result from various etiologies including
•  Fetal origin, eg congenital heart disease (premature foramen ovale closure, large AV septal defect), hematologic (erythroblastosis fetalis, α-thalassemia due to hemoglobin Barts, chronic fetomaternal or twin-twin transfusion), infection (CMV, herpesvirus, rubella, sepsis, toxoplasma), pulmonary (cystic adenomatoid malformation, diaphragmatic hernia, with pulmonary hypoplasia, lymphangiectasia), renal (vein thrombosis, congenital nephrosis) and teratomas, skeletal malformations (achondroplasia, osteogenesis imperfecta, fetal neuroblastomatosis, storage disease, meconium peritonitis, idiopathic)
•  Placental Chorangioma, umbilical or chorionic vein thrombosis
 Maternal DM, toxemia  
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.


Relating to the placenta.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012
References in periodicals archive ?
Turning to new nonsurgical therapeutic possibilities, the dermatologist mentioned the application of placentally derived angiogenesis inhibitors, targeting of Glut-1 or the other antigens, and immunomodulatory therapy.
To verify if these methods could be implemented in the RNA-SNP ratio assay for placentally expressed genes on chromosome 21 (1, 4), we used an SNP (rs2187247) located in exon 2 of C21orf105 as a model system.
3, B and C, in the online Data Supplement) can be applied to clinical plasma samples (placental RNA from maternal plasma) and adapted easily to related placentally expressed genes on chromosome 21.
Future studies might address whether different placentally expressed transcripts are cleared from maternal plasma at similar time profiles.
Thus, our study provides useful baseline data for comparison with future studies on other circulating placentally expressed transcripts in maternal plasma.
For this reason it will be necessary to increase our knowledge of cell-free placentally derived mRNA molecules in maternal plasma, their expression changes during pregnancy and pregnancy-related pathologies, and their relationship with circulatory fetal DNA under such conditions (16).
Detection of fetal DNA and RNA in placentally derived syncytiotrophoblast microparticles generated in vitro.
Placentally derived fetal mRNA in the plasma was quantified by one-step real-time quantitative RT-PCR using an assay for corticotropin-releasing hormone (CRH) as described previously (6).
It is generally believed that in pregnant women the source of cell-free fetal nucleic acids is placentally derived apoptotic cells (9).
Comparison of fetal globin gene expression with placentally derived gene expression may allow us to definitively determine whether the increased fetal nucleic acids seen after 9 weeks of gestation in maternal plasma are from a placental or hematopoietic source (13).
It is generally believed that in pregnant women the source of cell-free fetal nucleic acids is placentally derived apoptotic cells (12), but it has recently been shown that some fetal DNA sequences are detectable in membrane-bound vesicles (13).
To convert the experimentally validated strategy as described in this study to a clinical diagnostic application, quantitative plasma analysis of a placentally expressed, chromosome 21-encoded mRNA (target gene) must be complemented by correction for experimental and biological variability.